- Home
- ODD vs AKRO Comparison
ODD vs AKRO Comparison
Compare ODD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- AKRO
- Stock Information
- Founded
- ODD 2018
- AKRO 2017
- Country
- ODD Israel
- AKRO United States
- Employees
- ODD N/A
- AKRO N/A
- Industry
- ODD
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- AKRO Health Care
- Exchange
- ODD Nasdaq
- AKRO Nasdaq
- Market Cap
- ODD 3.8B
- AKRO 3.9B
- IPO Year
- ODD 2023
- AKRO 2019
- Fundamental
- Price
- ODD $74.43
- AKRO $49.65
- Analyst Decision
- ODD Buy
- AKRO Strong Buy
- Analyst Count
- ODD 8
- AKRO 8
- Target Price
- ODD $54.63
- AKRO $82.50
- AVG Volume (30 Days)
- ODD 1.5M
- AKRO 1.9M
- Earning Date
- ODD 04-29-2025
- AKRO 05-12-2025
- Dividend Yield
- ODD N/A
- AKRO N/A
- EPS Growth
- ODD 45.36
- AKRO N/A
- EPS
- ODD 1.74
- AKRO N/A
- Revenue
- ODD $703,488,000.00
- AKRO N/A
- Revenue This Year
- ODD $23.69
- AKRO N/A
- Revenue Next Year
- ODD $20.31
- AKRO N/A
- P/E Ratio
- ODD $42.85
- AKRO N/A
- Revenue Growth
- ODD 26.83
- AKRO N/A
- 52 Week Low
- ODD $32.71
- AKRO $17.86
- 52 Week High
- ODD $74.50
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ODD 75.22
- AKRO 63.34
- Support Level
- ODD $62.12
- AKRO $44.94
- Resistance Level
- ODD $73.67
- AKRO $49.29
- Average True Range (ATR)
- ODD 2.99
- AKRO 3.33
- MACD
- ODD 0.22
- AKRO 0.67
- Stochastic Oscillator
- ODD 99.57
- AKRO 86.02
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.